The importance of target expression in personalised medicine
Dr Paolo Nuciforo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
We are involved in developing and validating biomarkers for pre-selecting the patient in clinical studies. We have a particular interest in the quantification of proteins; it’s something that is becoming very appealing and interesting. During this WIN Symposium it emerged that not only the presence of the genetic alteration is critical but also what is downstream and what is the expression of the genes involved in the pathway. This is at RNA level but also at the protein levels and we are studying this at Vall d’Hebron where the idea is to combine genetic information with expression data of the RNA and with the protein.
